Furmecil 15mg Capsule

Furmecil 15mg Capsule is a medicine prescribed by the doctor to treat advanced gastric (stomach) cancer, often in combination with other medicine.

It sometimes also treats Colorectal and Pancreatic Cancer. Furmecil 15mg Capsule a combination of three salts Tegafur, Gimeracil and Oteracil that inhibit cancer cell proliferation and growth by interuppting various growth mechanisms.

• Advanced Gastric Cancer
  

Furmecil 15mg Capsule is a chemical salt based anticancer medication.Therefore,it has several common side effects like any other medicine.Consult your doctor, if side effects persist for longer period of time.

• Bone marrow suppression
• Diarrhea
• Dehydration
• Nausea
• Vomiting
• Kidney problems or acute renal failure
• Electrolyte imbalance
• Excessive Tearing
• Nerve issues (numbness, tingling in hands/feet)
• Hair loss and skin rash
• Indigestion
• Fatigue
• Dizziness

• Furmecil 15mg Capsule is taken orally with water without breaking, chewing or biting the capsule.It should be taken on empty stomach.
• Follow the doctor's prescribed dosage and time.​​
  

Tegafur is converted into 5-fluorouracil (5-FU), which acts by inhibiting thymidylate synthase, thereby obstructing DNA and RNA synthesis in rapidly proliferating cancer cells; gimeracil enhances the levels of 5-FU by preventing its degradation, whereas oteracil mitigates gastrointestinal toxicity.

• Kobayakawa, M., & Kojima, Y. (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets and therapy, 193-201. https://pubmed.ncbi.nlm.nih.gov/22162925/
• Matt, P., van Zwieten‐Boot, B., Calvo Rojas, G., Ter Hofstede, H., Garcia‐Carbonero, R., Camarero, J., ... & Pignatti, F. (2011). The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). The Oncologist, 16(10), 1451-1457. https://pubmed.ncbi.nlm.nih.gov/21963999/
• Kinoshita, T., Nashimoto, A., Yamamura, Y., Okamura, T., Sasako, M., Sakamoto, J., ... & Nakajima, T. (2004). Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer, 7(2), 104-109. https://pubmed.ncbi.nlm.nih.gov/15224197/

• Zhang, X., Tian, X., Wei, Y., Deng, H., Ma, L., & Chen, Z. (2021). Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis. Journal of Oncology, 2021(1), 6690275.